Outcomes of melanoma in recipients of solid organ transplant - 24/04/13
, Leslie J. Christenson, MD a
Reprint requests: Clark C. Otley, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.Abstract |
Background |
There is concern that the immunologic tumor malignant melanoma (MM) may have worse outcomes in immunosuppressed hosts than in the general population.
Objective |
We sought to describe outcomes of MM in immunosuppressed solid organ transplant recipients and compare them with the general population.
Methods |
We conducted a retrospective review of medical charts and pathology slides of cases of MM and solid organ transplantation between 1978 and 2007, with comparison of outcomes.
Results |
In all, 48 MMs were identified in 43 transplant recipients. No patient with MM before transplant receipt had melanoma recurrence, subsequent metastasis, or death caused by melanoma. Of patients with MM diagnosed after transplantation, metastases developed in 3 patients, and two patients died of melanoma.
Limitations |
Retrospective review and low number of cases are limitations.
Conclusions |
Outcomes of MM in immunosuppressed transplant recipients appeared similar to those in prognostically matched nonimmunosuppressed hosts. The small number of cases limited statistical comparisons.
Le texte complet de cet article est disponible en PDF.Abbreviations used : AJCC, MM, NMSC
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 59 - N° 3
P. 405-417 - septembre 2008 Retour au numéro
Article précédent
- Does hormone therapy improve age-related skin changes in postmenopausal women? : A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women
- Tania J. Phillips, James Symons, Sandeep Menon, HT Study Group ∗
- Volunteers Needed
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?